{
  "docId": "019dd923-622c-750b-8b9a-cb61f3b5c0ba",
  "docSlug": "bb36c74f657a",
  "documentTitle": "Pulse Biosciences (PLSE)",
  "authorId": "61_White_Diamond_Research",
  "authorName": "White Diamond Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-05-03 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 10,
  "pageCount": 13,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "villain_critique",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a 'villain_critique' approach to undermine the company's clinical claims and market potential.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/10",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-10",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "To call this clinical outcome impressive, to our mind, is laughable.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70fa-7556-8663-e653fc5df918",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.84,
        "x": 0.08,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "It looks like PLSE’s CEO is trying to promote very mediocre data on thyroids. Indeed, the CEO talks about a selected 3 patients from the group of 30 included in the study...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2417d029-0831-4f60-9e35-d28b0d12d0e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.84,
        "x": 0.08,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "It seems that the total number of thyroid surgeries in the US, quoted in this 2022 paper, is approximately 140,000 per year...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a142ef14-218a-426d-ae4f-9571887d685d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.08,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Note: AngioDynamics does not report direct sales from Nanoknife. We traced the estimation by analyzing Q1 reports from 2021 to 2025...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7421478-ad48-4232-8c9b-2c983664be55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.84,
        "x": 0.08,
        "y": 0.41
      },
      "kind": "quote",
      "text": "We are very pleased by the quality of the preliminary data from our First-In-Human Feasibility Study conducted in Italy...",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb244e71-c765-440d-8fcf-0209ca4eddc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "We are very pleased by the quality of the preliminary data from our First-In-Human Feasibility Study conducted in Italy and presented at the American Thyroid Association 2024 Annual Meeting. The data presented on 30 patients in three distinct cohorts demonstrated our system's effectiveness in reducing nodule size. In Cohort 3, three patients received complete nodule treatment and achieved on average 83% volume reduction at one year and significant reductions in symptoms just one month after treatment without evidence of residual fibrosis or scarring that would routinely accompany radiofrequency ablation. — Pulse Biosciences CEO",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70fa-7556-8663-eb2ec15e85bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.84,
        "x": 0.08,
        "y": 0.31
      },
      "kind": "title",
      "text": "Pulse’s Early Clinical Results For Thryoid Ablation Are Weak",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86b239f7-3e62-40ad-8293-dc36bf1fbc5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.84,
        "x": 0.08,
        "y": 0.81
      },
      "kind": "title",
      "text": "The Benign Thryoid Ablation Market Is Small",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdf585f7-4e55-4cae-9103-07f7272edd33",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "villain_critique",
      "slug": null,
      "matchId": "63198f9c-9406-4220-bcca-2a060fff4ebc",
      "evidence": "The slide explicitly frames the company's claims as 'mediocre' and 'laughable' to discredit them.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "17111959-043c-4444-914f-d47e7b87f2ca",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Villain Critique",
      "beatSlug": null,
      "evidence": "The document critiques Pulse Biosciences' leadership and market claims, portraying them as weak and unstable.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1ef62e8b-adc1-441c-a66b-e6fcf4ca1475",
      "evidence": "The document implies that investors who do not take action to address Pulse Biosciences' challenges will suffer financial losses.",
      "position": 1,
      "objective": "To highlight the cost of inaction for investors",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}